Novartis Opens New Radioligand Therapy Manufacturing Facility in California to Boost U.S. Cancer Treatment Capacity Read more
FDA Approves Johnson & Johnson’s DARZALEX FASPRO as First Treatment for High-Risk Smoldering Multiple Myeloma Read more
UCB Secures FDA Approval for KYGEVVI, the First-Ever Treatment for Ultra-Rare TK2 Deficiency Read more